Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Grows By 24.6%

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 82,236 shares, an increase of 24.6% from the March 15th total of 65,987 shares. Based on an average daily trading volume, of 46,188 shares, the short-interest ratio is currently 1.8 days. Currently, 2.2% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Friday, March 27th. Wall Street Zen raised shares of vTv Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Roth Mkm assumed coverage on shares of vTv Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price objective for the company. BTIG Research reissued a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, March 11th. Finally, TD Cowen assumed coverage on shares of vTv Therapeutics in a research note on Monday, January 5th. They issued a “buy” rating for the company. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $53.00.

vTv Therapeutics Stock Performance

Shares of NASDAQ:VTVT opened at $37.72 on Thursday. The firm has a fifty day moving average price of $36.53 and a 200 day moving average price of $32.44. vTv Therapeutics has a fifty-two week low of $14.00 and a fifty-two week high of $44.00. The firm has a market cap of $148.62 million, a price-to-earnings ratio of -11.26 and a beta of 0.40.

vTv Therapeutics (NASDAQ:VTVT) last issued its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.51. The company had revenue of ($0.02) million for the quarter.

Hedge Funds Weigh In On vTv Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of VTVT. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics during the fourth quarter valued at $221,000. Geode Capital Management LLC lifted its position in vTv Therapeutics by 84.3% during the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock valued at $1,128,000 after purchasing an additional 12,896 shares during the last quarter. 683 Capital Management LLC bought a new position in vTv Therapeutics during the fourth quarter valued at $731,000. Finally, Baker BROS. Advisors LP lifted its position in vTv Therapeutics by 52.4% during the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after purchasing an additional 51,000 shares during the last quarter. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.